

Note: This document is a translation of the original Japanese version and provided for reference purposes only. In the event of any discrepancy between the Japanese original and this English translation, the Japanese original shall prevail.

Press Release



Teijin Pharma and ASKA Pharmaceutical Enter Joint Research Agreement to Accelerate Discovery of Novel Small-Molecule Drug Candidates for Gynecological Diseases

TOKYO, February XX, 2026 - [ASKA Pharmaceutical Co., Ltd.](#) (Head Office: Minato-ku, Tokyo/President, Representative Director: Sohta Yamaguchi, hereinafter “ASKA”), a subsidiary of [ASKA Pharmaceutical Holdings Co., Ltd.](#) (TSE:4886), and [Teijin Pharma Limited](#) (Head Office: Chiyoda-ku, Tokyo; President and Representative Director: Masaki Taneda) have entered into a joint research agreement aimed at creating novel small-molecule drug candidate compounds targeting gynecological diseases. Details are shown in the attachment.

Media Contacts

ASKA Pharmaceutical Holdings Co., Ltd.
Corporate Planning Department
Tel: +81-3-5484-8366
Email: kouhou@aska-pharma.co.jp

NEWS RELEASE

Teijin Pharma and ASKA Pharmaceutical Enter Joint Research Agreement to Accelerate Discovery of Novel Small-Molecule Drug Candidates for Gynecological Diseases

Tokyo, February XX, 2026 - [Teijin Pharma Limited](#) (Head Office: Chiyoda-ku, Tokyo; President and Representative Director: Masaki Taneda; hereinafter “Teijin Pharma”), the core company of the [Teijin Group](#)’s healthcare business, and [ASKA Pharmaceutical Co., Ltd.](#) (Head Office: Minato-ku, Tokyo; President and Representative Director: Sohta Yamaguchi; hereinafter “ASKA”) announced today that it has entered into a joint research agreement aimed at creating novel small-molecule drug candidate compounds targeting gynecological diseases.

1. Background and History

- i. In the process of creating small-molecule drugs, compounds that act on molecules serving as therapeutic targets (“hit compounds”) are first identified from among a vast number of compounds. Subsequently, the structures of these hit compounds are optimized step by step to identify small-molecule drug candidate compounds that possess the desired efficacy, pharmacokinetic properties, and safety.
- ii. Teijin Pharma has been promoting the advancement and efficiency of compound discovery and structural optimization by utilizing Computer-Aided Drug Design (hereinafter “CADD”) and AI-based drug discovery technologies. Through highly accurate molecular design based on simulations and predictive models, Teijin Pharma has established a research platform that is expected to accelerate the drug discovery process and improve the probability of success.
- iii. ASKA, as a specialty pharma company with strengths in the fields of obstetrics and gynecology, urology, and internal medicine (gastroenterology and thyroid), has accumulated a drug discovery foundation rooted in real-world clinical needs. In particular, ASKA places emphasis on unmet medical needs in women’s total healthcare and has developed many products that support women throughout their life stages.
- iv. This agreement was concluded with the aim of accelerating the creation of new small-molecule drug candidate compounds in the field of gynecological diseases and achieving the early creation of innovative new drugs, by combining Teijin Pharma’s CADD and AI-based drug discovery technologies with ASKA’s disease expertise in the gynecological field, pharmacological evaluation platform, and drug discovery know-how.

2. Future Outlook

By combining the strengths of both companies, Teijin Pharma and ASKA aim to accelerate the drug discovery process and enhance the probability of success. In addition, they will work toward the early realization of innovative therapies that contribute to resolving unmet needs in the gynecological field and to the realization of healthy and comfortable lives for people.

Press Contact

Corporate Communication Department Teijin Limited E-mail: pr@teijin.co.jp	Corporate Planning Department, ASKA Pharmaceutical Co., Ltd. E-mail: kouhou@aska-pharma.co.jp
--	---